Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed/Refractory Multiple Myeloma
June 26th 2023Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shares the long-term findings from the pivotal CARTITUDE-1 trial, and highlights future directions for CAR T-cell therapy in this disease.
Dr Jänne on BL-B01D1 in NSCLC and Other Solid Tumors
June 21st 2023Pasi A. Jänne, MD, PhD, discusses findings from a first-in-human phase 1 trial investigating the EGFRxHER3 bispecific antibody-drug conjugate BL-B01D1 in patients with advanced non–small cell lung cancer and other advanced solid tumors.
NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy
Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.
What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?
Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.
Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer
June 6th 2023Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in patient with pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.
Cabozantinib/Atezolizumab Combo Misses PFS, OS End Points in ICI-Treated, Advanced RCC
The addition of atezolizumab to cabozantinib did not improve progression-free survival or overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma who previously received treatment with an immune checkpoint inhibitor, missing the primary end points of the phase 3 CONTACT-03 trial.
Cabozantinib Plus Nivolumab and Ipilimumab Provides PFS Benefit in Advanced RCC
May 20th 2023The addition of cabozantinib to nivolumab and ipilimumab led to improved progression-free survival vs nivolumab and ipilimumab alone in patients with treatment-naïve advanced renal cell carcinoma; however, the rate of grade 3/4 adverse effects with the triplet was 79%.
Osimertinib Plus Chemotherapy Improves PFS in EGFR+ Advanced NSCLC
The combination of osimertinib and platinum-based chemotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.
Three-drug Combination Slows Progression of Advanced Kidney Cancer
May 16th 2023A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.
International Study Shows Many Younger Women with Breast Cancer Can Safely Have a Baby
May 9th 2023A new study published today in the New England Journal of Medicine found that for young women with hormone receptor-positive breast cancer, pausing endocrine therapy to pursue a pregnancy did not raise the short-term risk that the disease will recur.